Key facts
- Nia Therapeutics’s last known valuation is $69.0M (Jun 2025).
- It has raised $22.0M across 1 recorded rounds; the latest was Early Stage VC ($23.6M) in Dec 2021.
- Notable investors include Creative Destruction Lab, University of Toronto, University of Toronto Entrepreneurship, Johnson & Johnson Innovation - JLABS, Ben Franklin Technology Partners of Southeastern Pennsylvania — 10 tracked in total.
- Nia Therapeutics has filed 2 Form Ds with the SEC since 2025, most recently Mar 2026 ($18.8M sold to 33 investors).
- Status: Privately Held (backing).
Investors
10- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Nia Therapeutics
Funding rounds
1 roundsAbout Nia Therapeutics
Developer of a neurostimulation device designed to stimulate memory for patients with traumatic brain injury. The company's device interprets the complex brain activity related to memory function and provides personalized therapy with the help of deep-brain stimulation devices, enabling patients with traumatic brain injury to improve memory by restoring the brain activity associated with good memory.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2016
- Employees
- 17
- Website
- niatx.com/
- Ownership
- Privately Held (backing)
Nia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.